Life Sciences · Strategy & Fundraising

Your execution
partner in
life sciences.

VV. Advisory partners with life sciences start-ups and VC funds to accelerate — delivering valuation studies, investor materials, data rooms and strategic intelligence. On-demand. No overhead. No lock-in.

Recent Mandates View all
€7M
Exit Valuation July 2026
Series A · Byome Labs — DCF, rNPV, acquirer mapping, exit scenarios €200–300M.
€17M
Pitch Deck March 2026
Series B · Vetbiolix — End-to-end investor pitch deck for their Series B roadshow.
€7M
Data Room June 2026
Series A · Byome Labs — Full data room architecture for fundraising.
+ 2 more mandates View all →
Exit Valuation Investor Mapping Pitch Decks Data Room Architecture LP Databases Strategic Intelligence Business Plans Acquirer Mapping Exit Valuation Investor Mapping Pitch Decks Data Room Architecture LP Databases Strategic Intelligence Business Plans Acquirer Mapping

Our Expertise

What we deliver

01
Valuation & Exit Analysis

Standalone DCF, rNPV modelling, comparable transactions, acquirer mapping across strategic buyer categories. Exit scenarios with sensitivity analyses — delivered as Excel model + investor presentation.

02
Data Room Architecture

End-to-end creation — structure, content, narrative flow, document production. Built to convert investor interest into conviction at every stage of due diligence.

03
Pitch Deck Creation

Short Deck (20p), Master Deck (50p), Two-pager, Annex Decks. Story-driven, investor-grade, co-built through structured iterations with your team.

04
Investor & LP Mapping

Structured databases of 200+ VC investors for start-ups and 300+ LPs for funds — institutional, HNWI, family offices, corporates — curated by sector, stage, and fit.

& other on-scope mandates

Business plans, ecosystem mapping, strategic intelligence, external communications — any one-time execution need, scoped on demand.

All mandates delivered on a one-time or recurring basis — no retainer, no overhead, no lock-in.

Track Record

Mandates delivered

Discuss a mandate
July 2026
Exit Valuation
€7M
Series A · Byome Labs

Strategic and financial valuation study — Standalone DCF, rNPV integrating milestone probabilities, full acquirer mapping across three strategic buyer categories with sensitivity analyses.

Dermatology ⏱ 30 days
March 2026
Pitch Deck
€17M
Series B · Vetbiolix

End-to-end investor pitch deck for Vetbiolix's Series B roadshow in veterinary drug development.

Veterinary Biotech ⏱ 30 days
June 2026
Data Room
€7M
Series A · Byome Labs

End-to-end data room — structure, content architecture, narrative flow and document production. Built to convert investor interest into conviction at every stage of due diligence.

Dermatology ⏱ 15 days
Feb. 2026
VC Mapping
200+
Health Start-up · $20M+ Fundraising

200+ international VC funds identified with key contacts and direct emails for a health start-up's $20M+ fundraising round.

Health Innovation ⏱ 7 days
Jan. 2026
LP Mapping
300+
Healthcare VC Fund · €100M Fundraising

Structured database of 300+ institutional LPs — family offices, corporates, HNWI — for a healthcare VC fund's €100M fundraising round.

VC Fund ⏱ On scope

Client Testimonial

Trusted by innovators

"

The collaboration with Victor went seamlessly in the context of optimising our corporate documents for our Series B roadshow in veterinary drug development. His ability to rapidly grasp the strategic stakes of Vetbiolix, then produce content that was both sharp and compelling, proved invaluable. His strong command of VC expectations in global life sciences significantly improved the clarity and impact of the investment case we presented.

Vetbiolix SAS
Veterinary Biotech · Series B · €17M fundraising · March 2026
Investor Pitch Deck

Currently active

More mandates
in progress.

Additional references and case studies available upon request.

Request references

Let's work together

Ready to
accelerate?

Tell us about your mandate — valuation, pitch deck, data room, investor mapping. We scope fast and start faster.

Send a brief →
Website vvadvisory.fr
Focus Biotech · MedTech · Digital Health · VC Funds
Scope One-time mandates · No retainer · No overhead
Response Within 24h — mandate scoped in 48h